Source comparison
BPC-157 Studied Carpal Tunnel: Research vs Clinical Reality Comparison
Nerve Conduction Recovery 35–40% faster return to baseline CMAP amplitude (Krivic et al., 2019) No published human trials as of 2026 Strong pre-clinical signal; human translation uncertain due to dosing and administration route differences Inflammation Reducti
This comparison does not assign a generated winner or score.
- Nerve Conduction Recovery
- 35–40% faster return to baseline CMAP amplitude (Krivic et al., 2019)
- No published human trials as of 2026
- Strong pre-clinical signal; human translation uncertain due to dosing and administration route differences
- Inflammation Reduction
- 50% reduction in IL-6 and TNF-alpha at compression sites within 14 days
- No published human trials
- Mechanism plausible but unverified in humans; NSAIDs remain first-line with established safety profiles
- Functional Recovery (Grip Strength)
- 40% faster grip strength restoration in rats with combined nerve/tendon injury (2020 study)
- Functional outcomes in rodents don't reliably predict human outcomes; structural nerve repair ≠ symptom relief
- Administration Route
- All studies used subcutaneous injection at 10 mcg/kg daily
- Oral peptides available but bioavailability unknown
- Injection bypasses gastric degradation; oral forms unlikely to achieve therapeutic plasma levels
- Safety Profile
- No adverse events reported in 8-week rodent studies
- No published human safety data
- Short-term rodent safety doesn't predict human tolerability; longer-term effects unexplored
- Mechanism of Action
- Upregulation of VEGF, NGF, bFGF; modulation of NF-kB and COX-2 pathways
- Proposed but not confirmed in human tissue
- Mechanism biologically coherent but lacks human validation; effect size may differ across species